Biotechnology
News Category
GeoVax Reports Second Quarter 2026 Financial Results and Advances GEO-MVA Towards Pivotal Immunobridging Study
GeoVax Labs reported a net loss of $4.4 million for Q2 2026 and provided updates on its lead programs, including preparation for a pivotal immunobridg...
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
Quantum BioPharma Outlines Strategy for Lucid-MS and Commercial Growth in BioMedWire Podcast
Quantum BioPharma's executive discusses the development plan for Lucid-MS, a potential multiple sclerosis treatment, alongside the commercial potentia...
Onco-Innovations Advances Lead Oncology Candidate ONC010 Toward Clinical Studies
Onco-Innovations Limited is progressing its lead oncology candidate ONC010, a PNKP inhibitor, by scaling up manufacturing, forming partnerships for dr...
Tonix Pharmaceuticals to Report Second-Quarter 2026 Financial Results on August 10
Tonix Pharmaceuticals announced it will release Q2 2026 financial results and operational highlights before a conference call on August 10, 2026, prov...
VERAXA Biotech Advances Bispecific ADC Program with OmniAb, Targeting Solid Tumors with Precision 'AND-Gate' Approach
VERAXA Biotech AG (NASDAQ: VRXA) has advanced its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, leveraging...
Onco-Innovations Integrates PNKP Inhibition, Nanoparticle Delivery, and AI to Tackle Cancer Drug Development Challenges
Onco-Innovations combines a novel PNKP inhibitor, nanoparticle delivery, and AI via its Inka Health subsidiary to address resistance, trial costs, and...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Drive BiTAC Platform Development
VERAXA Biotech names Christoph Erkel, Ph.D., as chief scientific officer to lead advancement of its BiTAC platform for solid tumor cancer therapies, s...
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC®-TCE Development
VERAXA Biotech has obtained Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead BiTAC®-TCE progra...
Onco-Innovations Advances Precision Oncology with Lead Candidate ONC010
Onco-Innovations is developing ONC010, a biomarker-driven cancer therapy, aligning with the industry shift toward precision medicine.
Lantern Pharma Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
Lantern Pharma announced a U.S. patent allowance for methods using a three-gene biomarker signature to select patients for LP-184 therapy, advancing p...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as chief scientific officer to lead the development of its proprietary BiTAC platform for cancer t...
iOrganBio Appoints Stem Cell Authority Lee L. Rubin, Ph.D. to Scientific Advisory Board
iOrganBio expands its Scientific Advisory Board with Lee L. Rubin, Ph.D., a leading stem cell biologist and Harvard professor, to advance its CellForg...
BioAdaptives Completes Manufacturing Readiness for Wellness Product Launch
BioAdaptives has finalized manufacturing and logistics for its upcoming MyndSystem and Xcellara wellness platforms, targeting cognitive performance an...
Creative Biolabs Expands Microfluidics Platform to Accelerate High-Throughput Antibody Discovery
Creative Biolabs has enhanced its microfluidics portfolio with integrated droplet generation systems and customizable chips to improve screening throu...
Quantum BioPharma Develops Dual Approach to Neurological Disorders, Targeting MS and Alcohol Effects
Quantum BioPharma (QNTM) is advancing treatments for multiple sclerosis with Lucid-MS and alcohol intoxication with unbuzzd, addressing significant un...
Oncotelic Therapeutics Publishes Preclinical Data Supporting Intravenous Cancer Therapy with Sapu003
Oncotelic Therapeutics announced publication of preclinical data for Sapu003, an intravenous everolimus formulation, supporting its Phase 1 trial in a...
Kairos Pharma Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer
Kairos Pharma has partnered with Bayer to test its antibody ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer, ai...
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC(R)-TCE Development
VERAXA Biotech AG announced that Germany's Paul-Ehrlich-Institute has provided Scientific Advice supporting the development strategy for its lead BiTA...
VivoSim Labs Announces $4 Million Private Placement with Healthcare-Focused Investor
VivoSim Labs, Inc. has secured $4 million in a private placement to fund working capital and general corporate purposes, highlighting its focus on adv...
Greenwich LifeSciences Advances Phase 3 Trial for Breast Cancer Immunotherapy GLSI-100
Greenwich LifeSciences reports DSMB recommends continuation of Phase 3 FLAMINGO-01 trial for GLSI-100, with plans to expand enrollment to 2,000 patien...
Quantum BioPharma Targets Two Major Neurological Disorders with Novel Pipeline
Quantum BioPharma is developing Lucid-MS for multiple sclerosis and unbuzzd for alcohol intoxication, addressing significant unmet needs in neurologic...
American Fusion Secures Texas Regulatory Approval for Texatron Fusion Engine Testing
American Fusion Inc. received a Texas DSHS Certificate of Registration for its Texatron Fusion Engine systems, enabling testing at Texas Tech Universi...
WHO Study Finds No Evidence That Mobile Phones Cause Brain Cancer
A comprehensive World Health Organization review of 13 studies found no link between mobile phone use and brain cancer, offering reassurance to billio...
Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study with Promising Early Results
Quantum BioPharma announced that its pilot imaging study for multiple sclerosis has reached halfway enrollment and shown encouraging preliminary data,...
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
GeoVax Labs emphasizes that its GEO-MVA vaccine platform aligns with the U.S. Department of Health and Human Services' five-year preparedness strategy...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE cancer therapy program, providing clarity on develop...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech announced regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE cancer therapy, advancing the program toward clin...
Regentis Biomaterials Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Regentis Biomaterials announced a Japan patent allowance for its proprietary solvent-free manufacturing process for GelrinC, a regenerative treatment ...
MindBio Therapeutics Advances AI-Powered Voice Analysis for Real-Time Impairment Detection
MindBio Therapeutics is developing an AI voice analysis platform to detect drug and alcohol impairment in real time, targeting workplace safety in ind...
Gut Microbial Metabolites Linked to Improved Immunotherapy Response in Cancer Patients
A recent study identifies metabolites produced by gut bacteria that enhance cancer immunotherapy efficacy, offering a potential biomarker and therapeu...
SS Innovations Appoints New CFO as Global Robotic Surgery Expansion Accelerates
SS Innovations International has appointed veteran medtech finance executive Sarah M. Romano as CFO, strengthening its leadership as the company pursu...
Creative Biolabs Unveils Integrated Microfluidics and Electrochemical Biosensor Platform for POCT Diagnostics
Creative Biolabs announced a platform combining microfluidics and electrochemical biosensors to enable rapid, lab-grade point-of-care testing for mole...
BioAdaptives Outlines Xcellara Platform Strategy Ahead of XcellaraHeart Launch
BioAdaptives details the scientific strategy behind its Xcellara cellular wellness platform, which combines stem cell mobilization with tissue-specifi...
NeuroOne Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial
NeuroOne Medical Technologies Corporation announced a collaboration with Mayo Clinic to evaluate a novel treatment approach for pediatric diffuse midl...
Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform to Support Biotech Drug Development
Oncotelic Therapeutics has introduced an AI-driven manufacturing services platform integrating its PDAOAI architecture with robotic automation to help...
Quantum BioPharma Advances Multiple Sclerosis Therapy with LUCID-MS, Paving Way for Phase 2 Trial
Quantum BioPharma's LUCID-MS, a neuroprotective therapy targeting myelin restoration, shows favorable safety in Phase 1 and is set for Phase 2 trials,...
VERAXA Biotech's AI Collaboration Could Provide Edge in Cancer Drug Development
VERAXA Biotech's partnership with Ardigen to leverage AI for target discovery and validation may enhance its BiTAC oncology platform, potentially redu...
Tonix Pharmaceuticals Publishes Mpox Research Supporting TNX-801 Vaccine Development
New preclinical research published in the Journal of Virology reveals that the mpox clade IIb strain is up to 100,000 times less virulent than clade I...
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline Programs
Nuvectis Pharma announced the pricing of a $100 million public offering to fund the development of its NXP100, NXP200, and NXP900 programs, including ...
Kairos Pharma Reports Favorable Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
Kairos Pharma announced positive interim safety results from its Phase 1 trial of ENV-105 combined with osimertinib for advanced EGFR-mutated NSCLC, s...
NeuroThera Labs Initiates Phase IIb Trial at Hannover Medical School for Tourette Syndrome Treatment
NeuroThera Labs has started a Phase IIb clinical trial at Hannover Medical School in Germany for SCI-110, a cannabinoid-based treatment for Tourette S...
Earth Science Tech Leverages Proprietary Tech and Strategic Positioning to Expand in Telehealth and Peptide Markets
Earth Science Tech Inc. is advancing its market position through vertical integration and proprietary technology, targeting the rapidly growing telehe...
Formycon and OneSource Specialty Pharma Forge Strategic Biosimilar Manufacturing Partnership
Formycon AG and OneSource Specialty Pharma have announced a strategic partnership for biosimilar manufacturing, leveraging OneSource's integrated Drug...
Quantum BioPharma Advances LUCID-MS Toward Phase 2 Trial for Multiple Sclerosis
Quantum BioPharma reports favorable Phase 1 safety data for its MS therapy LUCID-MS and plans a Phase 2 trial, positioning it as a potential first-in-...
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis into Phase 2 Trials
Quantum BioPharma reports positive Phase 1 safety data for its neuroprotective therapy LUCID-MS and prepares for Phase 2 trials in multiple sclerosis ...
Silo Pharma Subsidiary QwikAgents Joins AMD AI Developer Program
Silo Pharma's subsidiary QwikAgents has been accepted into AMD's AI Developer Program, which will accelerate development of its AI agent platform thro...
VERAXA Biotech’s AI Collaboration Highlights Growing Role of Artificial Intelligence in Drug Discovery
VERAXA Biotech has partnered with Ardigen to leverage AI for target discovery in its BiTAC cancer therapy platform, reflecting a broader trend where A...